<DOC>
	<DOCNO>NCT00233441</DOCNO>
	<brief_summary>Double blind study evaluate efficacy tolerability SSR149744C select dose investigated maintenance sinus rhythm electrical , pharmacological spontaneous conversion AF/AFL .</brief_summary>
	<brief_title>Placebo Controlled Double-blind Dose Ranging Study Efficacy Safety SSR149744C 50 , 100 , 200 300 mg OD With Amiodarone Calibrator Maintenance Sinus Rhythm Patients With Recent Atrial Fibrillation/Flutter</brief_title>
	<detailed_description>This dose-ranging multicenter , multinational , randomize , double-blind , placebo-controlled , parallel arm study 4 SSR149744C dose regimens amiodarone calibrator.To eligible , patient must normal sinus rhythm least one hour randomization must electrocardiogram documented history recent AF/AFL revert normal sinus rhythm electrical , pharmacological spontaneous conversion .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Patients age 21 year either sex document sinus rhythm least 1 hour time randomization least one ECGdocumented AF/AFL episode last 3 month . MAIN CRITERIA ( nonexhaustive list ) : Women childbearing potential without adequate birthcontrol , Pregnant Women , Breastfeeding woman , contraindication amiodarone , condition increase risk severe antiarrhythmic drug side effect , severe leave ventricular dysfunction , severe associate condition .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Atrial Flutter</keyword>
	<keyword>Arrhythmia</keyword>
	<keyword>Anti-Arrhythmia Agents</keyword>
</DOC>